Demographic, antenatal and delivery details
| Demographics | |
| Gestational age at delivery (weeks) | 26.1 (24.6–28) |
| Birth weight (g) | 730 (620–910) |
| Birth weight <10th centile | 57/153 (37.3%) |
| Male | 95/153 (62.1%) |
| Female | 58/153 (37.9%) |
| Antenatal steroids | |
| Received any steroid | 139/153 (90.8%) |
| Incomplete course only | 16/139 (11.5%) |
| One complete course | 109/139 (78.4%) |
| Two complete courses | 13/139 (9.4%) |
| Courses not known | 1/139 (0.7%) |
| None | 13/153 (8.5%) |
| Not known | 1/153 (0.7%) |
| Antenatal steroid received | |
| Betamethasone | 66/139 (47.5%) |
| Dexamethasone | 65/139 (46.8%) |
| Betamethasone and dexamethasone | 1/139 (0.7%) |
| Not known | 7/139 (5.0%) |
| Mode of delivery | |
| Caesarean section | 85/153 (55.6%) |
| Vaginal | 64/153 (41.8%) |
| Not known | 4/153 (2.6%) |
| Rupture of membranes | |
| Prelabour | 65/153 (42.5%) |
| Prolonged (>24 hours) | 46/153 (30.1%) |
| Placenta | |
| Evidence of chorioamnionitis | 21/153 (13.7%) |
| Other abnormality | 21/153 (13.7%) |
| Apgar scores | |
| 5 min | 7 (5–8) |
| 10 min | 8 (7–9) |
| Surfactant | |
| Doses received | |
| None | 1/153 (0.7%) |
| One | 58/153 (37.9%) |
| Two | 50/153 (32.7%) |
| ≥Three | 33/153 (21.6%) |
| Not known | 11/153 (7.2%) |
| Respiratory support at 36 weeks’ CGA | |
| Invasive ventilation | 13/94 (13.8%) |
| CPAP/BiPAP | 32/94 (34%) |
| High flow | 43/94 (45.7%) |
| Not known | 6/94 (6.4%) |
| Respiratory support at 38 weeks’ CGA | |
| Invasive ventilation | 13/94 (13.8%) |
| CPAP/BiPAP | 20/94 (21.3%) |
| High flow | 56/94 (59.6%) |
| Not known | 5/94 (5.3%) |
Data presented as number (%) or median (IQR).
BiPAP, bilevel positive airway pressure; CGA, corrected gestational age; CPAP, continuous positive airway pressure.